Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 28 10 2019
revised: 15 01 2020
accepted: 16 01 2020
pubmed: 9 2 2020
medline: 29 9 2020
entrez: 9 2 2020
Statut: ppublish

Résumé

Despite being one of the major pathways for the spread of malignant tumours, perineural invasion (PNI) has not conclusively been shown to have an independent prognostic value for prostate cancer. Prostatic biopsy constitutes the major pathology workload in prostate cancer and is the foundation for primary treatment decisions and for this reason we aimed to estimate the prognostic value of PNI in biopsies. We followed 918 men who underwent radical prostatectomy (RP) from the prospective and population based STHLM3 study until biochemical recurrence with a median follow-up of 4.1 years. To strengthen the evidence, we combined the estimates from the largest studies targeting the prognostic value of PNI in the biopsy. We also estimated the OR of advanced stage as radical prostatectomy for PNI positive and negative men. The estimated prognostic value based on our data suggested an approximately 50% increased risk of biochemical recurrence if PNI was present in the biopsy (p=0.06). Even though not statistically significant on the 5% level, this estimate is consistent with similar studies, and by combining the estimates there is in fact strong evidence in support of an independent prognostic value of PNI in the biopsy (p<0.0001). There was also an independent increased risk of advanced stage at RP for positive men (OR 1.85, p=0.005). The evidence supporting a clinically relevant and independent prognostic value of PNI is strong enough to be considered for pathology reporting guidelines.

Identifiants

pubmed: 32034057
pii: jclinpath-2019-206300
doi: 10.1136/jclinpath-2019-206300
pmc: PMC7513266
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

630-635

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Urology. 2013 Feb;81(2):354-7
pubmed: 23374801
Cancer. 2009 Aug 1;115(15):3379-91
pubmed: 19484787
Lancet Oncol. 2015 Dec;16(16):1667-76
pubmed: 26563502
J Urol. 1999 Jul;162(1):103-6
pubmed: 10379750
Eur J Epidemiol. 2016 Jun;31(6):563-74
pubmed: 27179798
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
Eur Urol. 2018 Aug;74(2):204-210
pubmed: 29331214
J Neurol Surg B Skull Base. 2016 Apr;77(2):124-30
pubmed: 27123388
J Urol. 2011 Feb;185(2):515-6
pubmed: 22088629
Mod Pathol. 2018 Jan;31(S1):S96-109
pubmed: 29297497
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Eur Urol. 2013 Mar;63(3):419-25
pubmed: 23083803
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
BMC Urol. 2018 Feb 1;18(1):5
pubmed: 29390991
BJU Int. 2010 Jun;105(11):1510-3
pubmed: 19694710
Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7
pubmed: 4026129

Auteurs

Peter Ström (P)

Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Tobias Nordström (T)

Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Sciences, Danderyd University Hospital, Stockholm, Sweden.

Brett Delahunt (B)

Pathology and Molecular Medicine, Wellington School of Medicine, Wellington, New Zealand.

Hema Samaratunga (H)

Aquesta Pathology, Brisbane, Queensland, Australia.

Henrik Grönberg (H)

Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology, S:t Göran Hospital, Stockholm, Sweden.

Lars Egevad (L)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Martin Eklund (M)

Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden martin.eklund@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH